Patents by Inventor Hartmut Rutten

Hartmut Rutten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
    Publication number: 20120202795
    Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Philip M. WEINTRAUB, Paul R. EASTWOOD, Shujaath MEHDI, David W. STEFANY, Kwon Yon MUSICK, Neil MOORCROFT, Sungtaek LIM, John Z. JIANG, Hartmut RUTTEN, Stefan PEUKERT, Uwe SCHWAHN
  • Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP)
    Patent number: 8173682
    Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: May 8, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Philip M. Weintraub, Paul R. Eastwood, Shujaath Mehdi, David W. Stefany, Kwon Yon Musick, Neil Moorcroft, Sungtaek Lim, John Z. Jiang, Hartmut Rutten, Stefan Peukert, Uwe Schwahn
  • SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
    Publication number: 20070032489
    Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Application
    Filed: September 26, 2006
    Publication date: February 8, 2007
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Philip Weintraub, Paul Eastwood, Shujaath Mehdi, David Stefany, Kwon Musick, Neil Moorcroft, Sungtaek Lim, John Jiang, Hartmut Rutten, Stefan Peukert, Uwe Schwahn
  • Imidazolidine derivatives, their preparation and their use
    Patent number: 6962937
    Abstract: The present invention relates to novel imidazolidine derivatives of the formula I, in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings given herein. The compounds of the formula I are valuable pharmaceutically active compounds which are suitable, for example, for treating inflammatory diseases, for example, rheumatoid arthritis, or allergic diseases. The compounds of the formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, which belongs to the integrin group. They are generally suitable for treating diseases which are caused by, or associated with, an undesirable degree of leukocyte adhesion and/or leukocyte migration or in which cell-cell or cell-matrix interactions, which are based on the interactions of VLA-4 receptors with their ligands, play a role.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: November 8, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Volkmar Wehner, Stefanie Flohr, Horst Blum, Hartmut Rütten, Hans Ulrich Stilz
  • Imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
    Patent number: 6680333
    Abstract: The present invention relates to novel imidazolidine derivatives of formula I, wherein A, E, Z, R1, R2, R3, R4 and R5 have the meanings indicated in the claims. The compounds of formula I are valuable pharmaceutical active compounds which are suitable, for example, for the treatment of inflammatory diseases, including rheumatoid arthritis, or allergic diseases. The compounds of formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the treatment of diseases which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on the interactions of VLA-4 receptors with their ligands play a role.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: January 20, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Volkmar Wehner, Horst Blum, Hartmut Rütten, Hans Ulrich Stilz
  • Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker
    Patent number: 6593352
    Abstract: Substituted anthranilic acids of the formula I their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: July 15, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Hans-Willi Jansen, Heinz-Werner Kleemann, Hans-Jochen Lang, Hartmut Rütten
  • Novel imidazolidine derivatives, their preparation and their use
    Publication number: 20030109497
    Abstract: The present invention relates to novel imidazolidine derivatives of the formula I, 1
    Type: Application
    Filed: July 31, 2002
    Publication date: June 12, 2003
    Inventors: Volkmar Wehner, Stefanie Flohr, Horst Blum, Hartmut Rutten, Hans Ulrich Stilz
  • Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
    Publication number: 20030073723
    Abstract: The present invention relates to novel imidazolidine derivatives of formula I, 1
    Type: Application
    Filed: March 8, 2002
    Publication date: April 17, 2003
    Inventors: Volkmar Wehner, Horst Blum, Hartmut Rutten, Hans Ulrich Stilz
  • Use of inhibitors of the sodium-hydrogen exchanger for the production of a medicament for decreasing undesired effects of substrates of the heart
    Patent number: 6462024
    Abstract: Inhibitors of the sodium-hydrogen exchanger are used for the production of a medicament for decreasing the undesired effects in human and in veterinary medicine which originate from substances which cause damage to the heart when administered acutely or chronically.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: October 8, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Hans Jochen Lang, Hartmut Rütten, Holger Heitsch, Wolfgang Linz, Bernward Schölkens
  • Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker
    Publication number: 20020123632
    Abstract: Substituted anthranilic acids of the formula I 1
    Type: Application
    Filed: December 6, 2001
    Publication date: September 5, 2002
    Inventors: Andreas Weichert, Hans-Willi Jansen, Heinz-Werner Kleemann, Hans-Jochen Lang, Hartmut Rutten